Black Hawk Acquisition (BKHA) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Black Hawk Acquisition is the larger company by market cap ($7.7 million vs $4.6 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | SNTI |
|---|---|---|
| Share price | $1.85 | $1.77 |
| Market cap | $7.68M | $4.60M |
| 1-day change | -71.45% | -36.56% |
| YTD return | — | +70.19% |
| 1-year return | — | -8.76% |
| 5-year return | — | -98.23% |
| P/E ratio (TTM) | 5.61 | — |
| EPS (TTM) | $0.33 | $-46.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $22.00K |
| Net income (latest FY) | $1.33M | $-61.44M |
| Operating margin | — | -312631.82% |
| Net margin | — | -279263.64% |
| 52-week high | $23.00 | $95.04 |
| 52-week low | $1.75 | $1.71 |
| Distance from 52-week high | -91.96% | -98.14% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +662.71% |
| Average volume | 101.40K | 108.98K |
| Shares outstanding | 4.15M | 2.60M |
| Employees | — | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
BKHA vs SNTI FAQ
Which is bigger, Black Hawk Acquisition or Senti Biosciences?
Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $7.68M compared with $4.60M for Senti Biosciences (SNTI).
Are Black Hawk Acquisition and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.